查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1981445

DNA與基因晶片市場：2026-2032年全球市場預測（按產品類型、晶片類型、應用和最終用戶分類）

DNA & Gene Chip Market by Product, Chip Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，DNA 和基因晶片市值將達到 108.4 億美元，到 2026 年將成長到 120.9 億美元，到 2032 年將達到 236.4 億美元，複合年成長率為 11.78%。

主要市場統計數據
基準年 2025 108.4億美元
預計年份：2026年 120.9億美元
預測年份 2032 236.4億美元
複合年成長率 (%) 11.78%

簡要概述了影響 DNA 和基因晶片生態系統的技術基礎、相關人員需求和策略重點，以輔助策略決策。

本執行摘要首先對DNA和基因晶片領域進行了簡要概述。它說明了定義當前市場趨勢、相關人員需求和實際應用案例的技術基礎。探針設計、小型化和數據分析的進步塑造了該領域的未來發展前景，而這些技術演進又與臨床需求、學術研究和工業應用緊密相連。基於此背景，讀者可以期待一份兼顧科學細微和商業性意義的分析報告。

技術融合、先進分析和不斷發展的經營模式正在重塑整個 DNA 和基因晶片價值鏈的功能和消費者期望。

在工程、資訊科學和臨床應用等多方面力量的融合推動下，DNA和基因晶片技術正經歷著變革性的轉變。小型化和探針密度的提高不斷擴大分析通量，使得以往需要多個平台才能完成的實驗能夠整合到單一晶片的工作流程中。同時，表面化學和雜合反應反應動力學的改進提高了靈敏度和重複性，從而增強了效用。

貿易政策和關稅因素的變化正在推動整個行業的供應鏈重新設計、採購多元化以及對法規的更大程度遵守。

近期貿易政策的發展和關稅考量正對DNA和基因晶片市場產生實際影響，迫使企業調整籌資策略、供應商關係和產業計畫。許多零件和耗材的供應鏈仍然高度集中於特定地區，關鍵材料和製造能力分散在各個國際樞紐。關稅措施可能會增加整體成本，擾亂現有的採購節奏，促使企業尋求供應商多元化並重新評估庫存策略。

細分市場的趨勢揭示了產品設計、應用需求、最終用戶工作流程和晶片化學特性如何相互交織，從而決定採用率和商業性差異化。

細分市場分析揭示了不同產品類型、應用、終端用戶和晶片類型之間的價值來源和採用模式的差異。在產品層面，標籤和檢測試劑盒作為前端試劑仍然至關重要，它們決定著檢測的靈敏度和特異性；而微陣列晶片正逐漸成為高通量分析工作流程的基礎，並在數據生成基板方面發揮主導作用。微流體耗材推動了樣品處理方式的創新，並支援微型化檢測。此外，qPCR 陣列提供了實驗室用於驗證陣列觀察結果的正交檢驗途徑。軟體和服務在從原始資料中提取價值方面正變得至關重要，它們透過提供分析、工作流程自動化和法規文檔，加快了獲得洞見的速度。

區域創新中心、法律規範和基礎設施成熟度在全球市場中形成了獨特的採用路徑和策略挑戰。

區域洞察揭示了全球各地不同的創新中心、法規環境和應用速度。美洲地區擁有先進的學術生態系統、強大的臨床市場以及大規模的生物技術和製藥活動，正在加速高通量平台和整合服務模式的早期應用。北美地區的診斷檢查室和製藥研發團隊專注於監管合規、臨床檢驗和可重複的工作流程，而私人企業則擴大投資於國內生產能力和合作夥伴關係，以降低供應鏈風險。

高效能製造、檢驗的工作流程和可互通的分析能力，再加上策略夥伴關係關係和明確的智慧財產權，為供應商創造了競爭優勢。

競爭格局的核心在於那些在晶片製造領域擁有卓越技術，並具備強大的試劑、軟體和服務商業生態系統的公司。主要企業正投資於整合解決方案，透過將高密度晶片和最佳化的標記化學與檢驗的工作流程和分析技術相結合，減輕終端用戶的負擔。策略合作和交叉授權協議加速了技術的應用，並使用戶能夠獲得樣品製備和雲端數據分析等互補功能。同時，規模小規模、高度專業化的供應商則透過細分市場差異化展開競爭，提供客製化耗材、客製化探針組或針對特定實驗或臨床需求量身定做的模組化軟體。

為高階主管提供將互通分析、供應鏈彈性和協同檢驗整合到可擴展經營模式的實用策略步驟。

產業領導者應採取一系列切實可行的措施，使創新、營運和商業化與不斷變化的市場動態保持一致。首先，應優先考慮平台互通性，並投資於能夠將原始陣列和晶片數據轉化為臨床和商業性適用洞察的軟體功能。無縫的數據工作流程將降低醫院和生物製藥客戶的採用門檻，並透過軟體訂閱和分析服務創造持續合作的機會。

透過結合相關人員訪談、技術文獻和供應鏈圖譜的嚴謹研究途徑，得出檢驗且可操作的產業見解。

本研究途徑採用定性和定量相結合的方法，以確保獲得平衡且基於證據的見解。主要參與者包括學術和研究機構的技術負責人、醫院和診斷中心的實驗室主任、製藥和生物技術公司的高級研發和採購負責人，以及合約研究組織（CRO）的高階主管，並對他們進行了深入訪談。透過這些訪談，我們探討了產品性能特徵、採購因素、檢驗要求和夥伴關係選擇標準。

技術進步、業務永續營運和以客戶為中心的商業化相結合，將決定企業的長期行業領導地位。

總之，DNA和基因晶片產業正處於一個轉折點，技術成熟度、數據驅動的價值創造和經營模式創新將決定其競爭優勢。晶片化學和微流體的進步拓展了實驗的可能性，而整合軟體和分析技術則將複雜的輸出結果轉化為研究人員、臨床醫生和產業合作夥伴可執行的決策。從學術和研究機構到醫院、合約研究組織（CRO）和製藥公司，終端用戶的多樣性要求制定靈活的產品藍圖和量身定做的檢驗策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：DNA與基因晶片市場：依產品分類

  • 識別牌和檢測工具包
  • 微陣列晶片
  • 微流體耗材
  • qPCR晶片
  • 軟體和服務

第9章：以晶片類型分類的DNA和基因晶片市場

  • cDNA 晶片
  • 寡核苷酸陣列

第10章：DNA與基因晶片市場：依應用分類

  • 診斷
    • 癌症診斷
    • 遺傳疾病的診斷
    • 感染疾病診斷
  • 基因表現分析
  • 基因型鑒定
  • 重測序

第11章：DNA與基因晶片市場：依最終用戶分類

  • 學術研究機構
  • 合約研究機構
  • 醫院和診斷檢查室
  • 製藥和生物技術公司

第12章 DNA與基因晶片市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：DNA與基因晶片市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 DNA與基因晶片市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國DNA與基因晶片市場

第16章：中國DNA與基因晶片市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Greiner Bio-One International GmbH
  • Illumina, Inc.
  • Integrated Dna Technologies
  • LifeGen Technologies, LLC
  • Macrogen Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-521BAA36EBAB

The DNA & Gene Chip Market was valued at USD 10.84 billion in 2025 and is projected to grow to USD 12.09 billion in 2026, with a CAGR of 11.78%, reaching USD 23.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.84 billion
Estimated Year [2026] USD 12.09 billion
Forecast Year [2032] USD 23.64 billion
CAGR (%) 11.78%

A concise orientation to technological pillars, stakeholder needs, and strategic priorities shaping the DNA and gene chip ecosystem for strategic decision-making

This executive summary opens with a concise orientation to the DNA and gene chip arena, describing the technological pillars, stakeholder imperatives, and practical use cases that define current market activity. The landscape is shaped by advances in probe design, miniaturization, and data analytics, and these technical evolutions intersect with clinical demand, academic inquiry, and industrial application. Against this backdrop, readers should expect a synthesis that balances scientific nuance with commercial implications.

The introduction frames core objectives: to clarify where innovation concentrates, to identify end-user needs across research and clinical environments, and to profile how product categories and chip types enable distinct workflows. It also outlines how regulatory trends, supply chain resilience, and strategic partnerships influence adoption trajectories. With these priorities established, the remainder of the document provides granular sectoral insights, cross-cutting risks, and practical recommendations for stakeholders seeking to align R&D, manufacturing, and go-to-market initiatives with emergent opportunities.

Technological convergence, advanced analytics, and evolving commercial models are reshaping capabilities and buyer expectations across the DNA and gene chip value chain

The landscape for DNA and gene chip technologies is experiencing transformative shifts driven by converging forces in engineering, informatics, and clinical translation. Miniaturization and higher probe density continue to expand analytical throughput, enabling experiments that once required multiple platforms to be consolidated onto single-chip workflows. Concurrently, improvements in surface chemistries and hybridization kinetics have increased sensitivity and reproducibility, which enhances utility in both research and diagnostic contexts.

At the same time, data science and machine learning have moved from experimental adjuncts to essential components of product value propositions. Sophisticated software pipelines now extract actionable insights from complex expression profiles and genotyping arrays, and vendors who integrate robust analytics with hardware offerings create differentiated solutions. These technological advances coincide with a shift in end-user expectations: academic and research institutes demand flexible, reproducible platforms for discovery, contract research organizations prioritize throughput and standardization, hospitals and diagnostic laboratories require clinically validated workflows, and pharmaceutical and biotechnology companies seek platforms that accelerate biomarker discovery and patient stratification.

Finally, business models are evolving. Software and services are increasingly bundled with consumables and instruments to create recurring revenue streams and deeper customer engagement. As a result, firms that invest in interoperable architectures, customer-centric service models, and partnerships across the value chain will have a strategic advantage in capturing long-term adoption and driving sustained innovation.

Trade policy shifts and tariff considerations have catalyzed supply chain redesigns, sourcing diversification, and regulatory diligence across the industry

Recent trade policy dynamics and tariff considerations have tangible implications for the DNA and gene chip landscape, altering sourcing strategies, supplier relationships, and operational planning. Many component and consumable supply chains remain geographically concentrated, with critical materials and manufacturing capacity located across international hubs. Tariff measures can increase landed costs and disrupt established procurement rhythms, prompting organizations to revisit supplier diversification and inventory policies.

In response, manufacturers and buyers have taken a range of mitigating actions. Some producers have accelerated efforts to localize production or qualify secondary suppliers to reduce exposure to trade uncertainty. Others have restructured contracts to allocate cost volatility more transparently between vendors and buyers, while logistics teams have adopted more dynamic inventory strategies to buffer short-term shocks. These adaptations often introduce additional lead time and require upfront capital, but they reduce the operational risk associated with abrupt policy shifts.

Regulatory compliance and customs classification also command greater attention. Companies spend more resources ensuring correct tariff classifications, pursuing exclusions where appropriate, and engaging with trade advisors to navigate evolving rules. At the same time, supply chain resilience has become a visible strategic priority within corporate governance, with scenario planning and supplier audits integrated into executive-level risk assessments. Ultimately, the cumulative impact of trade measures has catalyzed operational redesigns and strategic repositioning that extend beyond immediate cost effects to shape long-term sourcing, manufacturing, and partnership decisions.

Segment-specific dynamics reveal how product design, application demands, end-user workflows, and chip chemistry converge to determine adoption and commercial differentiation

Segmentation analysis reveals differentiated value drivers and adoption patterns across product categories, applications, end users, and chip types. Product-level dynamics show that labeling and detection kits remain indispensable as front-end reagents that determine assay sensitivity and specificity, while microarray chips anchor high-throughput profiling workflows and serve as the primary data-generating substrate. Microfluidics consumables enable sample handling innovations and support miniaturized assays, and qPCR arrays provide orthogonal validation pathways that laboratories use to confirm array-derived observations. Software and services have become central to deriving value from raw outputs, offering analytics, workflow automation, and regulatory documentation that accelerate time-to-insight.

Application-focused segmentation highlights diagnostic deployments alongside foundational research uses. Diagnostics includes cancer diagnostics, genetic disorder diagnostics, and infectious disease diagnostics, and each subtype imposes distinct requirements for analytical performance, validation, and turnaround. Gene expression profiling remains a core research application that informs mechanistic studies and biomarker discovery, whereas genotyping and resequencing activities cater to variant detection, population studies, and targeted interrogations. End-user segmentation differentiates needs across academic and research institutes, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies, with each segment prioritizing factors such as throughput, regulatory readiness, and integration with downstream R&D or clinical workflows.

Chip-type distinctions between cDNA arrays and oligonucleotide arrays further affect platform selection. cDNA arrays typically suit broader transcriptomic surveys and legacy workflows, while oligonucleotide arrays provide higher specificity and compatibility with modern probe design strategies. Consequently, product roadmaps that align chip chemistry with target applications and end-user operational constraints will capture greater adoption and enable more coherent commercial positioning.

Regional innovation hubs, regulatory frameworks, and infrastructure maturity create distinct adoption pathways and strategic imperatives across global markets

Regional insights expose differentiated innovation hubs, regulatory environments, and adoption rhythms across the globe. The Americas combine advanced academic ecosystems, robust clinical markets, and sizable biotechnology and pharmaceutical activity, which together foster early adoption of high-throughput platforms and integrated service models. North American diagnostic laboratories and pharma research teams emphasize regulatory alignment, clinical validation, and reproducible workflows, while commercial players increasingly invest in domestic manufacturing capacity and collaborative partnerships to reduce supply chain risk.

Europe, Middle East & Africa exhibits heterogeneity driven by strong translational research networks, consolidated clinical laboratory networks, and region-specific regulatory frameworks that emphasize patient safety and data integrity. In several European markets, centralized procurement and collaborative research consortia accelerate standardized platform adoption, whereas in some EMEA geographies, fragmented healthcare systems and variable infrastructure shape a more gradual uptake.

Asia-Pacific stands out for its large-scale manufacturing capabilities, expanding clinical diagnostics markets, and growing research funding. Regional manufacturing hubs support global supply chains for chips and consumables, and rising investments in genomic medicine push demand for both high-throughput discovery tools and clinical assays. Across these regions, differences in reimbursement policy, regulatory timelines, and infrastructure maturity inform go-to-market strategies and partnership models, making regionally tailored commercialization plans essential.

Competitive advantage accrues to providers that integrate high-performance manufacturing, validated workflows, and interoperable analytics with strategic partnerships and IP clarity

Competitive dynamics center on firms that blend technical excellence in chip fabrication with robust commercial ecosystems for reagents, software, and services. Leading companies invest in integrated offerings that reduce friction for end users, pairing high-density chips and optimized labeling chemistry with validated workflows and analytics. Strategic alliances and cross-licensing agreements accelerate technology diffusion and enable access to complementary capabilities such as sample preparation or cloud-based data interpretation. At the same time, smaller and more specialized vendors compete on niche differentiation-offering tailored consumables, bespoke probe sets, or modular software that address specific experimental or clinical needs.

Intellectual property and platform interoperability remain pivotal. Firms that secure broad patent coverage for probe designs, surface chemistries, and data processing methods can sustain premium positioning, while vendors that prioritize open standards and seamless integration drive broader ecosystem adoption. Manufacturing scale and quality systems influence pricing and reliability, particularly for customers in regulated environments. Finally, companies that demonstrate transparent validation pathways, responsive technical support, and clear regulatory strategies build stronger trust with hospitals, diagnostic labs, and pharmaceutical partners.

Practical strategic steps for executives to integrate interoperable analytics, supply chain resilience, and collaborative validation into scalable commercial models

Industry leaders should pursue a set of pragmatic actions to align innovation, operations, and commercialization with evolving market dynamics. First, prioritize platform interoperability and invest in software capabilities that turn raw array or chip data into clinically and commercially actionable insights. Seamless data workflows reduce adoption friction for hospitals and biopharma clients and create recurring engagement opportunities through software subscriptions and analytics services.

Second, strengthen supply chain resilience by qualifying multiple suppliers for critical components, assessing nearshoring options where feasible, and enhancing inventory visibility. These measures reduce vulnerability to trade policy shifts and logistical disruptions while maintaining service levels for diagnostic laboratories and research partners. Third, accelerate collaborative validation initiatives with end users across academic institutions, contract research organizations, and clinical labs to generate real-world evidence and streamline regulatory submission pathways. Such partnerships also refine product-market fit and shorten commercialization timelines.

Finally, adopt flexible commercial models that bundle consumables, instruments, and analytics into outcome-oriented offerings. Structured training, technical support, and application-specific pre-validated kits lower adoption barriers and improve customer retention. By executing on these priorities, organizations will convert technical superiority into sustainable market presence and long-term partnerships.

A rigorous research approach combining stakeholder interviews, technical literature, and supply chain mapping to generate validated and actionable industry insights

The research approach combined qualitative and quantitative techniques to ensure balanced, evidence-based insights. Primary engagement included in-depth interviews with technical leaders across academic and research institutes, laboratory directors from hospitals and diagnostic centers, senior R&D and procurement professionals at pharmaceutical and biotechnology companies, and executives at contract research organizations. These conversations explored product performance attributes, procurement drivers, validation requirements, and partnership preferences.

Secondary research encompassed technical literature, regulatory guidance documents, patent filings, and publicly available company disclosures to corroborate technological claims and trace historical development pathways. Supply chain mapping leveraged trade databases and manufacturing registries to identify concentration points for key components and assembly operations. Cross-validation steps synthesized primary feedback with secondary evidence to identify consistent patterns, stress test assumptions, and highlight divergent perspectives across regions and end users.

Analytical rigor was maintained through methodical source triangulation, documented interview protocols, and a transparent approach to classification of product, application, end-user, and chip-type segments. Where appropriate, sensitivity analyses helped contextualize operational risk factors such as tariff exposure and supplier concentration, enabling pragmatic recommendations grounded in observed market behavior.

Synthesis of technological progress, operational resilience, and customer-oriented commercialization that collectively determine long-term sector leadership

In conclusion, the DNA and gene chip sector stands at an inflection point where technical maturation, data-driven value creation, and commercial model innovation collectively define competitive advantage. Advances in chip chemistry and microfluidics expand experimental possibilities, while integrated software and analytics convert complex outputs into practical decisions for researchers, clinicians, and industry partners. End-user diversity-from academic and research institutes to hospitals, contract research organizations, and pharmaceutical companies-necessitates adaptable product roadmaps and tailored validation strategies.

Additionally, external pressures such as trade policies and evolving regulatory expectations have prompted organizations to revisit supply chain and sourcing strategies, reinforcing the importance of resilience and proactive risk management. Firms that align manufacturing capabilities, intellectual property, and interoperable analytics with customer-centric service models will be best positioned to capitalize on both near-term adoption and long-term growth opportunities. The overarching imperative is clear: integrate technical excellence with strategic operational design to transform scientific capability into reproducible, scalable value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA & Gene Chip Market, by Product

  • 8.1. Labeling And Detection Kits
  • 8.2. Microarray Chips
  • 8.3. Microfluidics Consumables
  • 8.4. qPCR Arrays
  • 8.5. Software And Services

9. DNA & Gene Chip Market, by Chip Type

  • 9.1. cDNA Arrays
  • 9.2. Oligonucleotide Arrays

10. DNA & Gene Chip Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Cancer Diagnostics
    • 10.1.2. Genetic Disorder Diagnostics
    • 10.1.3. Infectious Disease Diagnostics
  • 10.2. Gene Expression Profiling
  • 10.3. Genotyping
  • 10.4. Resequencing

11. DNA & Gene Chip Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals And Diagnostic Laboratories
  • 11.4. Pharmaceutical And Biotechnology Companies

12. DNA & Gene Chip Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. DNA & Gene Chip Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. DNA & Gene Chip Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States DNA & Gene Chip Market

16. China DNA & Gene Chip Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. BGI Genomics Co., Ltd
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Danaher Corporation
  • 17.9. F. Hoffmann-La Roche Ltd
  • 17.10. Greiner Bio-One International GmbH
  • 17.11. Illumina, Inc.
  • 17.12. Integrated Dna Technologies
  • 17.13. LifeGen Technologies, LLC
  • 17.14. Macrogen Inc.
  • 17.15. PerkinElmer, Inc.
  • 17.16. QIAGEN N.V.
  • 17.17. Takara Bio Inc.
  • 17.18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA & GENE CHIP MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA & GENE CHIP MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA & GENE CHIP MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA & GENE CHIP MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA & GENE CHIP MARKET SIZE, BY LABELING AND DETECTION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA & GENE CHIP MARKET SIZE, BY LABELING AND DETECTION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA & GENE CHIP MARKET SIZE, BY LABELING AND DETECTION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROARRAY CHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROARRAY CHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROARRAY CHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROFLUIDICS CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROFLUIDICS CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROFLUIDICS CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA & GENE CHIP MARKET SIZE, BY QPCR ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA & GENE CHIP MARKET SIZE, BY QPCR ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA & GENE CHIP MARKET SIZE, BY QPCR ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA & GENE CHIP MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA & GENE CHIP MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA & GENE CHIP MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CDNA ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CDNA ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CDNA ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA & GENE CHIP MARKET SIZE, BY OLIGONUCLEOTIDE ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA & GENE CHIP MARKET SIZE, BY OLIGONUCLEOTIDE ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA & GENE CHIP MARKET SIZE, BY OLIGONUCLEOTIDE ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CANCER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CANCER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CANCER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENETIC DISORDER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENETIC DISORDER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENETIC DISORDER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA & GENE CHIP MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA & GENE CHIP MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA & GENE CHIP MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA & GENE CHIP MARKET SIZE, BY RESEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA & GENE CHIP MARKET SIZE, BY RESEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA & GENE CHIP MARKET SIZE, BY RESEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA & GENE CHIP MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA & GENE CHIP MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA & GENE CHIP MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA & GENE CHIP MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA & GENE CHIP MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA & GENE CHIP MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA & GENE CHIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS DNA & GENE CHIP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GCC DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. GCC DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 122. GCC DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. G7 DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. G7 DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NATO DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 143. NATO DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NATO DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NATO DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)